{"id":"fap","name":"FAP","symbol":"FAP","route":"/targets/fap/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3590","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000078098","uniprot":"https://www.uniprot.org/uniprotkb/Q12884/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q12884","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4683","open-targets":"https://platform.opentargets.org/target/ENSG00000078098","civic":"https://civicdb.org/genes/2191/summary","oncokb":"https://www.oncokb.org/gene/FAP","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FAP","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=FAP","depmap":"https://depmap.org/portal/gene/FAP?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000078098-FAP","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2191","omim":"https://www.omim.org/entry/600403"}],"products":[{"id":"eb-mf-car-nk-01","name":"EB-MF-CAR-NK-01","status":"phase-2","modality":"bispecific antibody","route":"/drugs/eb-mf-car-nk-01/"},{"id":"fap-2286","name":"FAP-2286 (177Lu / 68Ga)","status":"phase-2","modality":"Theranostic pair (peptide radioligand)","route":"/drugs/fap-2286/"}],"trials":[{"id":"nct05939414","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","nct":"NCT05939414","phase":"3","status":"recruiting"},{"id":"nct06520345","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","nct":"NCT06520345","phase":"3","status":"recruiting"},{"id":"nct07219238","name":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o","nct":"NCT07219238","phase":"2/3","status":"recruiting"},{"id":"nct06894511","name":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","nct":"NCT06894511","phase":"2","status":"active"},{"id":"nct05142696","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","nct":"NCT05142696","phase":"1/2","status":"active"},{"id":"nct04939610","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","nct":"NCT04939610","phase":"1/2","status":"recruiting"},{"id":"nct05413850","name":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","nct":"NCT05413850","phase":"1/2","status":"recruiting"},{"id":"nct07510815","name":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","nct":"NCT07510815","phase":"1/2","status":"recruiting"},{"id":"nct07066995","name":"Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer","nct":"NCT07066995","phase":"1/2","status":"recruiting"}],"pathways":["immune-desert-exclusion","caf-activation-desmoplasia","invasion-ecm-degradation","tumor-microenvironment"],"companies":["novartis","ratio-therapeutics","sofie-biosciences"],"keyPapers":["paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017","paper-ozdemir-caf-depletion-accelerates-pancreatic-cancer-cancer-cell-2014","paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"pd1-blockade","mechanism":"Immune-desert / excluded tumours","category":"immune-evasion"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}